Trials / Completed
CompletedNCT01396590
Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects
A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine that six 2-mg tablets of perampanel are bioequivalent to one 12-mg tablet of perampanel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | 6 x 2 mg perampanel once per day |
| DRUG | Perampanel | 12 mg perampanel once per day |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2011-07-19
- Last updated
- 2012-05-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01396590. Inclusion in this directory is not an endorsement.